Quarterly Investor Update - Q3 FY23 Test Volumes rise 36%

GENERAL

Thu, Jan 19 2023 09:26 am

QUARTERLY INVESTOR UPDATE – Q3 FY23 TEST VOLUMES RISE 36% ON Q3 FY22

DUNEDIN, New Zealand -- Cancer diagnostics company Pacific Edge (NZX, ASX: PEB) has today released its Third Quarter Shareholder Update (attached) showing test volumes processed in its laboratories in the three months to the end of December 2022 increased 36% on the same three-month period a year ago.

In the three months to the end of December 2022 (Q3 23), Pacific Edge processed 7,768 tests. The 36% increase over the 5,708 processed in Q3 22, is a growth rate in line with the year-on-year growth rates the company achieved in Q2 23 and ahead of the year-on-year growth rate of 32% achieved in Q1 23.

Volumes were flat on the Q2 23’s 7,864 tests reflecting the traditional slowdown the company sees from Thanksgiving through to the New Year and the start of the fourth quarter. As the company has seen in prior years, it expects a return to quarter-on-quarter growth in Q4 23. Further detail on test volumes is covered in the shareholder update.

Released for and on behalf of Pacific Edge by Grant Gibson Chief Financial Officer.  
For more information:

Dr Peter Meintjes
Chief Executive
Pacific Edge
P: 022 032 1263

Richard Inder
The Project
P: 021 645 643

OVERVIEW www.pacificedgedx.com
Pacific Edge Limited (NZX/ ASX: PEB) is a global cancer diagnostics company leading the way in the development and commercialization of bladder cancer diagnostic and prognostic tests for patients presenting with hematuria or surveillance of recurrent disease. Headquartered in Dunedin, New Zealand, the company provides its suite of Cxbladder tests globally through its wholly owned, and CLIA certified, laboratories in New Zealand and the USA.

About Cxbladder www.cxbladder.com
Cxbladder is a non-invasive genomic urine test optimized for the detection and management of bladder cancer. The Cxbladder evidence portfolio developed over the past 14 years includes more than 20 peer reviewed publications for primary detection, surveillance, adjudication of atypical urine cytology and equivocal cystoscopy. Cxbladder is the focal point of numerous ongoing and planned clinical studies to generate an ever-increasing body of clinical utility evidence supporting adoption and use in the clinic to improve patient health outcomes. Cxbladder is reimbursed by CMS and has been trusted by over 2,000 US urologists in the diagnosis and management of more than 80,000 patients, including the option for in-home sample collection. In New Zealand, Cxbladder is accessible to 70% of the population via public healthcare and all residents have the option of buying the test online.